Literature DB >> 7561774

Association of hepatitis C virus particles with immunoglobulin: a mechanism for persistent infection.

S H Choo1, H S So, J M Cho, W S Ryu.   

Abstract

The physical properties of hepatitis C virus (HCV) particles were determined by ultracentrifugation on 20-60% isopycnic sucrose density gradients. We report that (i) two populations of HCV particles were found in the sera of patients with chronic HCV infection [at high density (1.186-1.213 g/ml) and at low density (1.099-1.127 g/ml)], (ii) virus particles with high density values were associated with immunoglobulin, and (iii) virus particles with low density values accumulated base changes within a hypervariable region (HVR) of the E2 envelope domain of the RNA genome. The results indicate that base changes within the HVR of E2 lead to the accumulation of immunoglobulin-free virus particles. Therefore, these findings imply that persistent HCV infection is established as a consequence of sequence variation in the E2 envelope domain.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561774     DOI: 10.1099/0022-1317-76-9-2337

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  19 in total

1.  Immune complex of hepatitis C virus particles detected by immunogold electron microscopy.

Authors:  Masahiko Kaito; Esteban C Gabazza; Naoki Fujita; Hideaki Tanaka; Shozo Watanabe; Michinori Kohara
Journal:  J Gastroenterol       Date:  2006-08       Impact factor: 7.527

2.  Persistence of Circulating Hepatitis C Virus Antigens-Specific Immune Complexes in Patients with Resolved HCV Infection.

Authors:  Ke-Qin Hu; Wei Cui
Journal:  Dig Dis Sci       Date:  2018-03-08       Impact factor: 3.199

3.  An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies.

Authors:  Birke Bartosch; Géraldine Verney; Marlène Dreux; Peggy Donot; Yoann Morice; François Penin; Jean-Michel Pawlotsky; Dimitri Lavillette; Francois-Loïc Cosset
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Quantitative measurement of hepatitis C virus core antigen is affected by the presence of cryoglobulins.

Authors:  B-N Pham; M Martinot-Peignoux; M-P Ripault; N Boyer; V Levy; P Marcellin
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

5.  Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients.

Authors:  P Maillard; K Krawczynski; J Nitkiewicz; C Bronnert; M Sidorkiewicz; P Gounon; J Dubuisson; G Faure; R Crainic; A Budkowska
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  Immune complexed (IC) hepatitis C virus (HCV) in chronically and acutely HCV-infected patients.

Authors:  E Riva; F Maggi; F Abbruzzese; F Bellomi; G Giannelli; A Picardi; C Scagnolari; A Folgori; E Spada; E Piccolella; F Dianzani; G Antonelli
Journal:  Med Microbiol Immunol       Date:  2008-08-12       Impact factor: 3.402

7.  Identification of a domain containing B-cell epitopes in hepatitis C virus E2 glycoprotein by using mouse monoclonal antibodies.

Authors:  J W Lee; K m Kim; S H Jung; K J Lee; E C Choi; Y C Sung; C Y Kang
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

8.  Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma.

Authors:  Mei-ying W Yu; Birke Bartosch; Pei Zhang; Zheng-ping Guo; Paula M Renzi; Li-Ming Shen; Christelle Granier; Stephen M Feinstone; François-Loïc Cosset; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-10       Impact factor: 11.205

9.  Characterization of low- and very-low-density hepatitis C virus RNA-containing particles.

Authors:  P André; F Komurian-Pradel; S Deforges; M Perret; J L Berland; M Sodoyer; S Pol; C Bréchot; G Paranhos-Baccalà; V Lotteau
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C.

Authors:  Joonho Yoon; Jong In Lee; Soon Koo Baik; Kwang Ho Lee; Joon Hyung Sohn; Hyean Woo Lee; Jun Namkung; Sei Jin Chang; Jong Whan Choi; Hyun Won Kim; Byung-Il Yeh
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.